Atenolol as a comparator in outcome trials in hypertension: A correct choice in the past, but not for the future?

Blood Pressure

Volumn 16, Issue 1, 2007, Pages 6-12

  Dahlöf, Björn ^a   Devereux, Richard B ^b   Kjeldsen, Sverre E ^c   Lyle, Paulette A ^d   Zhang, Zhongxin ^d   Edelman, Jonathan M ^d  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Beta blocker; Cardiovascular outcomes

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOSARTAN; METOPROLOL; PINDOLOL; PLACEBO; PROPRANOLOL;

ARTICLE; BIOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; HUMAN; HYPERTENSION; INCIDENCE; INFORMATION RETRIEVAL; ISCHEMIC HEART DISEASE; MEDLINE; META ANALYSIS; MORBIDITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CONTROL GROUPS; ENDPOINT DETERMINATION; HUMANS; HYPERTENSION; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 34247593470     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050701246386     Document Type: Article

References (36)

1. European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens, pp. 1011-1053.
2. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A. and Izzo, J. L Jr. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA, 289, pp. 2560-2572.
3. Messerli, F. H., Grossman, E. and Goldbourt, U. (1998) Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA, 279, pp. 1903-1907.
4. Messerli, F. H., Beevers, D. G., Franklin, S. S. and Pickering, T. G. (2003) beta-Blockers in hypertension - The emperor has no clothes: An open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens, 16, pp. 870-873.
5. Carlberg, B., Samuelsson, O. and Lindholm, L. H. (2004) Atenolol in hypertension: Is it a wise choice?. Lancet, 364, pp. 1684-1689.
6. Gail, M. and Simon, R. (1985) Testing for qualitative interactions between treatment effects and patient subsets. Biometrics, 41, pp. 361-372.
7. Coope, J. and Warrender, T. S. (1986) Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed), 293, pp. 1145-1151.
8. Medical Research Council trial of treatment of hypertension in older adults MRC Working Party. Br Med J, pp. 405-412.
9. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group Br Med J, pp. 703-713.
10. MRC trial of treatment of mild hypertension: Principal results Medical Research Council Working Party. Br Med J (Clin Res Ed), pp. 97-104.
11. Dahlöf, B., Lindholm, L. H., Hansson, L., Scherstén, B., Ekbom, T. and Wester, P. O. (1991) Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet, 338, pp. 1281-1285.
12. Zayas, V. M., Blumenfeld, J. D., Bading, B., McDonald, M., James, G. D. and Lin, Y. F. (1993) Adrenergic regulation of renin secretion and renal hemodynamics during deliberate hypotension in humans. Am J Physiol, 265, pp. F686-F692.
13. Blumenfeld, J. D., Sealey, J. E., Mann, S. J., Bragat, A., Marion, R. and Pecker, M. S. (1999) Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens, 12, pp. 451-459.
14. Dahlöf, B., Keller, S. E., Makris, L., Goldberg, A. I., Sweet, C. S. and Lim, N. Y. (1995) Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens, 8, pp. 578-583.
15. Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, N. H. and Eberlein, K. A. (1990) Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet, 335, pp. 827-838.
16. Dahlöf, B., Pennert, K. and Hansson, L. (1992) Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens, 5, pp. 95-110.
17. Norwegian Multicenter Study Group Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med, pp. 801-807.
18. Mulrow, C., Lau, J., Cornell, J. and Brand, M. Pharmacotherapy for hypertension in the elderly (Cochrane Review). The Cochrane Library, Issue 3, 2004, John Wiley & Sons, Ltd, Chichester
19. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke (1993) The Dutch TIA Trial Study Group. Stroke, 24, pp. 543-548.
20. Eriksson, S., Olofsson, B. O. and Wester PO for the TEST study group Atenolol in secondary prevention after stroke. Cerebrovasc Dis, pp. 21-25.
21. Collins, R., Peto, R., MacMahon, S., Hebert, P., Fiebach, N. H. and Eberlein, K. A. (1990) Blood pressure, stroke, and coronary heart disease: Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet, 335, pp. 827-838.
22. Thijs, L., Fagard, R., Lijnen, P., Staessen, J., Van Hoof, R. and Amery, A. (1992) A meta-analysis of outcome trials in elderly hypertensives. J Hypertens, 10, pp. 1103-1109.
23. Staessen, J. A., Wang, J. G., Thijs, L. and Fagard, R. (1999) Overview of the outcome trials in older patients with isolated systolic hypertension. J Hum Hypertens, 13, pp. 859-863.
24. Staessen, J. A., Wang, J. G. and Thijs, L. (2003) Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. J Hypertens, 21, pp. 1055-1076.
25. Turnbull, F. and Blood Pressure Lowering Treatment Trialists' Collaboration Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively designed overviews of randomised trials. Lancet, pp. 1527-1535.
26. Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G. and de Faire, U. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet, 359, pp. 995-1003.
27. Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G. and Caulfield, M. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet, 366, pp. 895-906.
28. Psaty, B. M., Smith, N. L., Siscovick, D. S., Koepsell, T. D., Weiss, N. S. and Heckbert, S. R. (1997) Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA, 277, pp. 739-745.
29. Wright, J. M. (2000) Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 2: Beta-blockers. CMAJ, 163, pp. 188-192.
30. Lindholm, L. H., Carlberg, B. and Samuelsson, O. (2005) Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 366, pp. 1545-1553.
31. Amery, A., Birkenhager, W., Bixko, P., Bulpitt, C., Clement, D. and Deruyttere, M. (1985) Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet, 1, pp. 1349-1354.
32. Kuramoto, K., Matsushita, S., Kuwajima, T. and Murakami, M. (1981) Prospective study on the treatment of mild hypertension in the aged. Jpn Heart J, 22, pp. 75-85.
33. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA, pp. 3255-3264.
34. Hulley, S. B., Furberg, C. D., Gurland, B., McDonald, R., Perry, H. M. and Schnaper, H. W. (1985) Systolic Hypertension in the Elderly Program (SHEP): Antihypertensive efficacy of chlorthalidone. Am J Cardiol, 56, pp. 913-920.
35. Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G. and Birkenhager, W. H. (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet, 350, pp. 757-764.
36. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: The International Prospective Primary Prevention Study in Hypertension (IPPPSH) The IPPPSH Collaborative Group. J Hypertens, pp. 379-392.